SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) reported today that initial results from its ongoing single-dose Phase I study of HE3286 for the treatment of metabolic disorders demonstrate the compound is orally bioavailable in humans, with significant drug concentrations detected in the blood at the lowest dose tested. The Company’s findings also show that all doses of HE3286 (10mg to 100mg) appear to be safe and well tolerated in healthy volunteers with no reported drug related adverse side effects to date. In addition the Company announced that certain of its preclinical data with HE3286 is being published by the New York Academy of Sciences. The published work demonstrates that HE3286, an orally bioavailable small molecule adrenal steroid hormone, produced a statistically significant reduction in disease in a rodent model of arthritis.
